Page 3 - Scientific Library
PARP and Top1 inhibitors most beneficial in endonuclease-deficient cancer cells
The synergistic combination of Poly(ADP-ribose) polymerases (PARP) and Topoisomerase I (Top1) inhibitors most beneficial on endonuclease-deficient cancer cells in cancer therapies ?
This is one
EndoG and ATM cell cycle checkpoint in Leukemogenesis
In a recent publication, Gole B. and Baumann C. demonstrate the role of the apoptotic nuclease EndoG in Mixed-Lineage Leukemia breakpoint cluster region (MLLbcr) destabilisation leading to MLL gene rearrangements
ATM or DNA-PKcs inhibitors synthetically lethal in BRCA- cells
Several lines of evidence show that synthetic lethal interactions targeting DNA repair pathways may have clinical applications in cancer therapy. In a recent paper, Albarakati et al. demonstrate
Tumor growth and metastasis monitored in vivo
In vivo monitoring of tumor growth and metastasis provides a powerful means for studying cancer properties and development of effective therapies. Mouse models created with tumor xenografts, resulting
CRISPR genome editing: which cell line to choose?
Many labs have adopted the CRISPR genome editing technology to make knock-out and knock-in cell lines.
This technology produces first a targeted break in genomic DNA, which can then be exploited
Ion channel over expressing cell lines for inhibitory screening
In a recent post on Venomous toxin ion channel modulators, we looked at toxin derived peptides to manipulate a wide variety of ion channels. These toxins can be used as tools to characterize
Crosstalk between cancer and immune cells: tumor escape
A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer and
Is tumour immune evasion mediated by p53/miR-34/PDL1 interaction?
Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .
The
Why is the hCMEC/D3 cell line a robust in vitro BBB model?
The Blood-Brain Barrier (BBB) affects the development of drugs for all pathologies (brain exposure to drugs, side effects...). In the early phases of drug development, there is a strong need for stable
New Reporter cell lines for Drug discovery and Immunotherapy checkpoint research
In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of
